Tag: Cytoxan

Cytoxan: Trade name of cyclophosphamide, a chemotherapy drug. Cytoxan is an alkylating agent frequently used in combination with anthracyclines (Adriamycin, epirubicin) and/or taxanes (Taxol, Taxotere).

News

12/07/11
10/09/11
12/10/10

Studies

  • Neuropsychological Performance in Survivors of Breast Cancer More Than 20 Years After Adjuvant Chemotherapy Cite
    Koppelmans V, Breteler MM, Boogerd W, Seynaeve C, Gundy C, Schagen SB. Neuropsychological Performance in Survivors of Breast Cancer More Than 20 Years After Adjuvant Chemotherapy. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:1080-1086 10.1200/jco.2011.37.0189
  • Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials Cite
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG) . Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. The Lancet. Elsevier BV; 2012; 379:432-444 10.1016/s0140-6736(11)61625-5
  • Twenty-five year results of the national cancer institute randomized breast conservation trial Cite
    Simone NL, Dan T, Shih J, Smith SL, Sciuto L, Lita E, et al. Twenty-five year results of the national cancer institute randomized breast conservation trial. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 132:197-203 10.1007/s10549-011-1867-6
  • Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer Cite
    Han Y, Yu Z, Wen S, Zhang B, Cao X, Wang X. Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 131:483-490 10.1007/s10549-011-1799-1
  • Adjuvant Trastuzumab in HER2-Positive Breast Cancer Cite
    Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant Trastuzumab in HER2-Positive Breast Cancer. New England Journal of Medicine. Massachusetts Medical Society; 2011; 365:1273-1283 10.1056/nejmoa0910383
  • Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer Cite
    Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, et al. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer. Wiley; 2011; 118:2385-2393 10.1002/cncr.26555
  • Synchronous Chemo-radiation Can Reduce Local Recurrence in Early Stage Breast Cancer: Results of the SECRAB Trial (ISRCTN: 84214355) Presented on Behalf of the SECRAB Steering Committee Cite
    Fernando I, Bowden S, Brookes C, Grieve R, Spooner D, Agrawal R, et al. Synchronous Chemo-radiation Can Reduce Local Recurrence in Early Stage Breast Cancer: Results of the SECRAB Trial (ISRCTN: 84214355) Presented on Behalf of the SECRAB Steering Committee. European Journal of Cancer. Elsevier BV; 2011; 47:2 10.1016/s0959-8049(11)70097-1
  • Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers Cite
    Lee LJ, Alexander B, Schnitt SJ, Comander A, Gallagher B, Garber JE, et al. Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers. Cancer. Wiley; 2011; 117:3093-3100 10.1002/cncr.25911
  • Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology Cite
    Eschenhagen T, Force T, Ewer MS, de Keulenaer GW, Suter TM, Anker SD, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. Wiley; 2011; 13:1-10 10.1093/eurjhf/hfq213
  • Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer Cite
    Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, et al. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer. Wiley; 2012; 118:5937-5946 10.1002/cncr.27527
  • Abstract P1-11-01: ANZAC: A Randomised Neoadjuvant Biomarker Study Investigating the Anti-Tumour Activity of the Addition of Zoledronic Acid to Chemotherapy in Breast Cancer Cite
    Winter M, Syddall S, Cross S, Evans A, Ingram C, Jolley I, et al. Abstract P1-11-01: ANZAC: A Randomised Neoadjuvant Biomarker Study Investigating the Anti-Tumour Activity of the Addition of Zoledronic Acid to Chemotherapy in Breast Cancer. Poster Session Abstracts. American Association for Cancer Research; 2010; 10.1158/0008-5472.sabcs10-p1-11-01
  • Hematologic toxicity with adjuvant docetaxel and cyclophosphamide in early breast cancer. Cite
    Santos FN, Cruz MR, Cezana L, Costa LA, de Azevedo CA, De Barros E Silva MJ, et al. Hematologic toxicity with adjuvant docetaxel and cyclophosphamide in early breast cancer.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:e11081-e11081 10.1200/jco.2010.28.15_suppl.e11081
  • Hepatotoxicity in breast cancer patients post-chemotherapy with docetaxel, doxorubucin, and cyclophosphamide. Cite
    Wills SM, Reid R, Jaiyesimi IA, Margolis JH. Hepatotoxicity in breast cancer patients post-chemotherapy with docetaxel, doxorubucin, and cyclophosphamide.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:e11031-e11031 10.1200/jco.2010.28.15_suppl.e11031
  • Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer Cite
    Cameron DA, Massie C, Kerr G, Leonard RCF. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. British Journal of Cancer. Springer Science and Business Media LLC; 2003; 89:1837-1842 10.1038/sj.bjc.6601366
  • Abstract 3223: Severe dietary restriction enhances cancer treatment: Protecting normal cells and sensitizing malignant cells to chemotherapy by fasting Cite
    Lee C, Safdie F, Raffaghello L, Wei M, Longo V. Abstract 3223: Severe dietary restriction enhances cancer treatment: Protecting normal cells and sensitizing malignant cells to chemotherapy by fasting. Cellular and Molecular Biology. American Association for Cancer Research; 2010; 10.1158/1538-7445.am10-3223
  • Decrease in Breast Density in the Contralateral Normal Breast of Patients Receiving Neoadjuvant Chemotherapy: MR Imaging Evaluation Cite
    Chen J, Nie K, Bahri S, Hsu C, Hsu F, Shih H, et al. Decrease in Breast Density in the Contralateral Normal Breast of Patients Receiving Neoadjuvant Chemotherapy: MR Imaging Evaluation. Radiology. Radiological Society of North America (RSNA); 2010; 255:44-52 10.1148/radiol.09091090
  • Antiproliferative Effects of Honey and of Its Polyphenols: A Review Cite
    Jaganathan SK, Mandal M. Antiproliferative Effects of Honey and of Its Polyphenols: A Review. Journal of Biomedicine and Biotechnology. Hindawi Limited; 2009; 2009:1-13 10.1155/2009/830616
  • Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer Cite
    Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, et al. Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2009; 27:3297-3302 10.1200/jco.2009.19.6410
  • Influence of orange juice over the genotoxicity induced by alkylating agents: an in vivo analysis Cite
    Franke SIR, Prá D, Erdtmann B, Henriques JAP, da Silva J. Influence of orange juice over the genotoxicity induced by alkylating agents: an in vivo analysis. Mutagenesis. Oxford University Press (OUP); 2005; 20:279-283 10.1093/mutage/gei034